Etanercept as steroid-sparing agent in dermatomyositis

Annals of Neurology

Volumn 70, Issue 4, 2011, Pages 670-671

  Brunasso, Alexandra Maria Giovanna ^a,b   Fancelli, Laura ^c   Massone, Cesare ^b  

^a GALLIERA HOSPITAL   (Italy)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

^c UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; IMMUNOGLOBULIN G; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR RECEPTOR;

CLINICAL ARTICLE; DERMATOMYOSITIS; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG FATALITY; DRUG WITHDRAWAL; HUMAN; LETTER; PRIORITY JOURNAL; QUALITY OF LIFE; RASH; FEMALE; MALE; NOTE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DERMATOMYOSITIS; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 84855408657     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.22624     Document Type: Letter

References (5)

1. The Muscle Study Group. A randomized, pilot trial of etanercept in dermatomyositis. Ann Neurol 2011;70427-436.
2. Dastmalchi M, Grundtman C, Alexanderson H, et al. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis 2008;671670-1677.
3. Klein R, Rosenbach M, Kim EJ, et al. Tumor necrosis factor inhibitor-associated dermatomyositis. Arch Dermatol 2010;146780-784.
4. Brunasso AM, Scocco GL, Massone C. Dermatomyositis during adalimumab therapy for rheumatoid arthritis. J Rheumatol 2010; 371549-1550.
5. Ishikawa Y, Yukawa N, Kawabata D, et al. A case of antisynthetase syndrome in a rheumatoid arthritis patient with anti-PL-12 antibody following treatment with etanercept. Clin Rheumatol 2011; 30429-432.